This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.Pompe is a rare disease caused by the deficiency of acid a glucosidase, an enzyme that breaks down lysosomal glycogen. The overall aim is to evaluate the safety, efficacy, and pharmacokinetics of Myozyme in patients with late-onset Pompe as compared to placebo. Myozyme is an investigational enzyme made by Genzyme Corp. to replace the missing enzyme in Pompe patients. We are applying as a secondary site. All subjects will begin the study at a primary site & transfer after receiving study drug infusions for 6 mos.
Showing the most recent 10 out of 945 publications